134 related articles for article (PubMed ID: 17457941)
1. The interaction of cationic polymers and their bisphosphonate derivatives with hydroxyapatite.
Zhang S; Wright JE; Ozber N; Uludağ H
Macromol Biosci; 2007 May; 7(5):656-70. PubMed ID: 17457941
[TBL] [Abstract][Full Text] [Related]
2. Cleavage of disulfide-linked fetuin-bisphosphonate conjugates with three physiological thiols.
Zhang S; Wright JE; Bansal G; Cho P; Uludag H
Biomacromolecules; 2005; 6(5):2800-8. PubMed ID: 16153121
[TBL] [Abstract][Full Text] [Related]
3. Imparting mineral affinity to fetuin by bisphosphonate conjugation: a comparison of three bisphosphonate conjugation schemes.
Gittens SA; Bansal G; Kucharski C; Borden M; Uludag H
Mol Pharm; 2005; 2(5):392-406. PubMed ID: 16196492
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonate-coated BSA nanoparticles lack bone targeting after systemic administration.
Wang G; Kucharski C; Lin X; Uludağ H
J Drug Target; 2010 Sep; 18(8):611-26. PubMed ID: 20158316
[TBL] [Abstract][Full Text] [Related]
5. Imparting bone mineral affinity to osteogenic proteins through heparin-bisphosphonate conjugates.
Gittens SA; Bagnall K; Matyas JR; Löbenberg R; Uludag H
J Control Release; 2004 Aug; 98(2):255-68. PubMed ID: 15262417
[TBL] [Abstract][Full Text] [Related]
6. Palmitic acid substitution on cationic polymers for effective delivery of plasmid DNA to bone marrow stromal cells.
Incani V; Tunis E; Clements BA; Olson C; Kucharski C; Lavasanifar A; Uludag H
J Biomed Mater Res A; 2007 May; 81(2):493-504. PubMed ID: 17340629
[TBL] [Abstract][Full Text] [Related]
7. A comparison of mineral affinity of bisphosphonate-protein conjugates constructed with disulfide and thioether linkages.
Wright JE; Gittens SA; Bansal G; Kitov PI; Sindrey D; Kucharski C; Uludağ H
Biomaterials; 2006 Feb; 27(5):769-84. PubMed ID: 16055182
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the effectiveness of cationic polymers poly-L-lysine (PLL) and polyethylenimine (PEI) for non-viral delivery of plasmid DNA to bone marrow stromal cells (BMSC).
Farrell LL; Pepin J; Kucharski C; Lin X; Xu Z; Uludag H
Eur J Pharm Biopharm; 2007 Mar; 65(3):388-97. PubMed ID: 17240127
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate conjugation to proteins as a means to impart bone affinity.
Uludag H; Kousinioris N; Gao T; Kantoci D
Biotechnol Prog; 2000; 16(2):258-67. PubMed ID: 10753453
[TBL] [Abstract][Full Text] [Related]
10. Imparting mineral affinity to proteins with thiol-labile disulfide linkages.
Bansal G; Wright JE; Zhang S; Zernicke RF; Uludag H
J Biomed Mater Res A; 2005 Sep; 74(4):618-28. PubMed ID: 16037953
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonate-decorated lipid nanoparticles designed as drug carriers for bone diseases.
Wang G; Mostafa NZ; Incani V; Kucharski C; Uludağ H
J Biomed Mater Res A; 2012 Mar; 100(3):684-93. PubMed ID: 22213565
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and in vitro hydroxyapatite binding of peptides conjugated to calcium-binding moieties.
Murphy MB; Hartgerink JD; Goepferich A; Mikos AG
Biomacromolecules; 2007 Jul; 8(7):2237-43. PubMed ID: 17530891
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate-derivatized liposomes to control drug release from collagen/hydroxyapatite scaffolds.
Wang G; Babadağli ME; Uludağ H
Mol Pharm; 2011 Aug; 8(4):1025-34. PubMed ID: 21557579
[TBL] [Abstract][Full Text] [Related]
14. Selectivity in bone targeting with multivalent dendritic polyanion dye conjugates.
Gröger D; Kerschnitzki M; Weinhart M; Reimann S; Schneider T; Kohl B; Wagermaier W; Schulze-Tanzil G; Fratzl P; Haag R
Adv Healthc Mater; 2014 Mar; 3(3):375-85. PubMed ID: 23996966
[TBL] [Abstract][Full Text] [Related]
15. Time-resolved fluorescence spectroscopy reveals functional differences of cationic polymer-DNA complexes.
Vuorimaa E; Urtti A; Seppänen R; Lemmetyinen H; Yliperttula M
J Am Chem Soc; 2008 Sep; 130(35):11695-700. PubMed ID: 18693688
[TBL] [Abstract][Full Text] [Related]
16. Adsorption of bisphosphonate onto hydroxyapatite using a novel co-precipitation technique for bone growth enhancement.
McLeod K; Anderson GI; Dutta NK; Smart RS; Voelcker NH; Sekel R; Kumar S
J Biomed Mater Res A; 2006 Nov; 79(2):271-81. PubMed ID: 16817191
[TBL] [Abstract][Full Text] [Related]
17. Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro.
Hengst V; Oussoren C; Kissel T; Storm G
Int J Pharm; 2007 Mar; 331(2):224-7. PubMed ID: 17150316
[TBL] [Abstract][Full Text] [Related]
18. Designing proteins for bone targeting.
Gittens SA; Bansal G; Zernicke RF; Uludağ H
Adv Drug Deliv Rev; 2005 May; 57(7):1011-36. PubMed ID: 15876401
[TBL] [Abstract][Full Text] [Related]
19. Improved bone delivery of osteoprotegerin by bisphosphonate conjugation in a rat model of osteoarthritis.
Doschak MR; Kucharski CM; Wright JE; Zernicke RF; Uludağ H
Mol Pharm; 2009; 6(2):634-40. PubMed ID: 19718808
[TBL] [Abstract][Full Text] [Related]
20. Adhesion between biodegradable polymers and hydroxyapatite: Relevance to synthetic bone-like materials and tissue engineering scaffolds.
Neuendorf RE; Saiz E; Tomsia AP; Ritchie RO
Acta Biomater; 2008 Sep; 4(5):1288-96. PubMed ID: 18485842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
